|
1) Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100: 3484-8
|
|
|
|
2) Trousseau A. Plegmasia alba dolens. In: Clinique Medicale de l'Hotel-Dieu de Paris, 2nd ed, Vol 3 Paris: JB Balliere et Fils. 1865. p. 654-712
|
|
|
|
|
|
3) Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003; 349: 109-11
|
|
|
|
|
|
4) Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006; 35: 103-10
|
|
|
|
|
|
5) Rak J, Milsom C, May L, et al. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost. 2006; 32: 54-70
|
|
|
|
|
|
6) Rak J, Yu JL, Luyendyk J, et al. Oncogenes, Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res. 2006; 66: 10643-6
|
|
|
|
|
|
7) Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005; 105: 1734-41
|
|
|
|
|
|
8) Parry GC, Mackman N. Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain. J Clin Invest. 2000; 105: 1547-54
|
|
|
|
|
|
9) Parry GC, Erlich JH, Carmeliet P, et al. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest. 1998; 101: 560-9
|
|
|
|
|
|
10) Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry. 1985; 24: 5558-67
|
|
|
|
|
|
11) Raasi S, Mielicki WP, Gordon SG, et al. Properties of proteins in cancer procoagulant preparations that are detected by anti-tissue factor antibodies. Arch Biochem Biophys. 2004; 428: 131-5
|
|
|
|
|
|
12) Kazmierczak M, Lewandowski K, Wojtukiewicz MZ, et al. Cancer procoagulant in patients with adenocarcinomas. Blood Coagul Fibrinolysis. 2005; 16: 543-7
|
|
|
|
|
|
13) Borsig L, Wong R, Hynes RO, et al. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A. 2002; 99: 2193-8
|
|
|
|
|
|
14) Wahrenbrock M, Borsig L, Le D, et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003; 112: 853-62
|
|
|
|
|
|
15) Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 2005; 11: 7003-11
|
|
|
|
|
|
16) Wahrenbrock MG, Varki A. Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the “tip of the iceberg"？ Cancer Res. 2006; 66: 2433-41
|
|
|
|
|
|
17) DiBaise JK, Donovan JP. Markedly elevated CA125 in hepatic cirrhosis: two case illustrations and review of the literature. J Clin Gastroenterol. 1999; 28: 159-61
|
|
|
|
|
|
18) Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999; 340: 994-1004
|
|
|
|
|
|
19) Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood. 1998; 91: 3093-102
|
|
|
|
|
|
20) Matsunaga T, Inaba T, Matsui H, et al. Regulation of annexin II by cytokine-initiated signaling pathways and E2A-HLF oncoprotein. Blood. 2004; 103: 3185-91
|
|
|
|
|
|
21) Madoiwa S, Someya T, Hironaka M, et al. Annexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis. Thromb Res. 2007; 119: 229-40
|
|
|
|
|
|
22) Denko NC, Giaccia AJ. Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res. 2001; 61: 795-8
|
|
|
|
|
|
23) Rong Y, Post DE, Pieper RO, et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005; 65: 1406-13
|
|
|
|
|
|
24) Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature. 2005; 434: 396-400
|
|
|
|
|
|
25) Madoiwa S, Nunomiya S, Ono T, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006; 84: 398-405
|
|
|
|
|
26) FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003; 2: 879-90
|
|
|
|
|
|
27) Nierodzik M, Karpatkin S. Hypercoagulability preceding cancer. Does hypercoagulability awaken dormant tumor cells in the host？ J Thromb Haemost. 2005; 3: 577-80
|
|
|
|
|
|
28) Duan HO, Simpson-Haidaris PJ. Functional analysis of interleukin 6 response elements (IL-6REs) on the human gamma-fibrinogen promoter: binding of hepatic Stat3 correlates negatively with transactivation potential of type II IL-6REs. J Biol Chem. 2003; 278: 41270-81
|
|
|
|
|
|
29) Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66, 329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006; 4: 529-35
|
|
|
|
|
|
30) Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002; 100: 1168-71
|
|
|
|
|
|
31) Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992; 327: 1128-33
|
|
|
|
|
|
32) Sorensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998; 338: 1169-73
|
|
|
|
|
|
33) Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293: 715-22
|
|
|
|
|
|
34) Miller GJ, Bauer KA, Howarth DJ, et al. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004; 2: 2107-14
|
|
|
|
|
|
35) Monreal M, Lensing AW, Prins MH, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost. 2004; 2: 876-81
|
|
|
|
|
|
36) Piccioli A, Lensing AW, Prins MH, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2004; 2: 884-9
|
|
|
|
|
|
37) Norgard-Sumnicht KE, Varki NM, Varki A. Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. Science. 1993; 261: 480-3
|
|
|
|
|
|
38) Nelson RM, Cecconi O, Roberts WG, et al. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood. 1993; 82: 3253-8
|
|
|
|
|
|
39) Kakkar AK. Low-molecular-weight heparins: beyond thrombosis in the management of the cancer patient. Semin Thromb Hemost. 2003; 29 Suppl 1: 13-5
|
|
|
|
|
|
40) Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002; 346: 975-80
|
|
|
|
|
|
41) Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349: 146-53
|
|
|
|
|
|
42) Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 2: 1266-71
|
|
|
|
|
|
43) Colman RW, Marder VJ, Clowes AW, et al. In: Hemostasis and Thrombosis-basic principles and clinical practice. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006
|
|
|
|
|
|
44) Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007; 110: 1723-29
|
|
|
|
|